PSP Research LLC Takes $547,000 Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Posted by George Bondi on May 20th, 2026

PSP Research LLC purchased a new stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 21,879 shares of the company’s stock, valued at approximately $547,000. Centessa Pharmaceuticals accounts for approximately 0.5% of PSP Research LLC’s holdings, making the stock its 13th biggest holding.

Other institutional investors and hedge funds also recently made changes to their positions in the company. TD Waterhouse Canada Inc. acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $25,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Centessa Pharmaceuticals by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock valued at $117,000 after buying an additional 979 shares during the period. DNB Asset Management AS acquired a new position in shares of Centessa Pharmaceuticals in the third quarter valued at approximately $218,000. Sigma Planning Corp acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $225,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Centessa Pharmaceuticals in the third quarter valued at approximately $455,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on CNTA. Leerink Partners cut shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and increased their target price for the stock from $36.00 to $40.00 in a report on Wednesday, April 1st. Wells Fargo & Company cut shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $35.00 to $42.00 in a report on Monday, April 20th. Stephens cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Truist Financial cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price for the company. in a report on Monday, April 13th. Finally, Lifesci Capital cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 1st. Four investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $40.70.

Read Our Latest Analysis on Centessa Pharmaceuticals

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $39.70 on Wednesday. The stock has a market cap of $5.92 billion, a P/E ratio of -22.18 and a beta of 1.13. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53. The company has a fifty day moving average price of $35.81 and a two-hundred day moving average price of $29.07. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $10.95 and a one year high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). As a group, equities analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Insider Transactions at Centessa Pharmaceuticals

In related news, insider Karen M. Anderson sold 120,029 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the transaction, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,629,731.25. This trade represents a 65.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gregory M. Weinhoff sold 73,196 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the transaction, the insider directly owned 65,925 shares in the company, valued at approximately $1,735,805.25. This represents a 52.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 309,112 shares of company stock worth $8,424,535. 4.09% of the stock is owned by insiders.

About Centessa Pharmaceuticals

(Free Report)

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.